Edison Investment Research - Pharmaceutical & healthcare - Immutep: We expect Immutep to deliver on a number of important milestones in the year ahead. The AIPAC Phase II study of its APC activator eftilagimod alpha (efti) plus chemo in breast cancer is expected to complete recruitment in H119 and report top-line data before the end of the year. The TACTI-002 study of efti plus Keytruda in lung and head and neck cancers in collaboration with US Merck will start shortly and report first data mid-year, whereas TACTI-mel will report first data from melanoma patients dosed with efti from the start of Keytruda therapy. Other in-house and partnered programmes are also likely to produce significant news. We maintain our valuation of A$510m ahead of these milestones.
ISIN: AU000000PRR9
Original Article: Immutep (IMM) - A big year ahead for efti